Search CommunityWalk:


Sirnaomics, Inc.

401 Professional Dr. Suite 130
Gaithersburg, MD, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

Sirnaomics, Inc. is a biopharmaceutical company specialized in discovering and developing targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology. It was established in 2007 by Patrick Y. Lu, David M. Evans, George J. Ji and Harry H. Yang, with a mission to advance RNAi technology using multi-targeted design of small interfering RNA (siRNA) and nanoparticle-enhanced delivery.

Sirnaomics uses its R4D approach to develop siRNA based therapeutics for significant markets in healthcare. R4D stands for Rapid Design, Discovery, Delivery and Development (of siRNAs for therapeutic development). Using a proprietary algorithm for siRNA sequence prediction against gene target of interest, it can rapidly identify siRNA sequences with Seven characteristics including (1) optimal thermodynamics, (2) enhanced RISC binding, (3) eliminated (or added) immune stimulating motifs, (4) minimized "Off-Target" potential, (5) having homology between human and mouse sequences (to facilitate ease of development), (6) patent searched and (7) no interaction when multiple sequences mixed in the cocktail.

Sirnaomics' delivery technologies allow selection of the best approach to ensure efficient and safe delivery of siRNAs to their target tissues. Its therapeutic programs are categorized into two stages: the programs in development and the programs in discovery. The company's therapeutics areas of interests include: siRNA therapeutics for skin scarless wound healing, respiratory influenza infection and ocular neovascularization diseases. Its pipeline products include: STP702 (FluQuit®), STP601 for AMD and Retinopathy, STP705 (Cutasil®) for Skin Scarless Wound Healing (SSWH), STP503 for Breast Cancer, STP801 for Non-Small Cell Lung Cancer (NSCLC), and STP523 for Glioblastoma Multiforme (GBM).

Sirnaomics has collaboration agreements with National Institute of Allergy and Infectious Diseases, The National Cancer Institute, University of Maryland, General Research Laboratory, Inc., etc.